Entrada Therapeutics, Inc. (TRDA) Key Metrics
TRDA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $170.2M
- Enterprise value
- $78.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 36.3 10-yr median 10.3
- Price / book
- 1.1 10-yr median 1.8
- EV / EBITDA
- 1.6
- Dividend yield
- —
- Beta
- −0.24
TRDA key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsTRDA valuation Price multiples at each fiscal year-end price.
TRDA returns How much profit the business earns on the capital it uses.
TRDA per-share figures Results divided by the shares outstanding at year-end.
TRDA financial health Debt, liquidity and how easily interest is covered.
TRDA efficiency & capital use Working capital cycle and where the cash goes.
TRDA valuation history
TRDA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TRDA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TRDA price vs earnings per share
TRDA key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $425.3M | $674.4M | $498.7M | $423.1M | $534.6M | — | — |
| Enterprise value | $180.5M | $313.6M | $215.0M | $260.3M | $243.5M | — | — |
| P/E ratio | — | 10.3 | — | — | — | — | — |
| Price / sales | 16.7 | 3.2 | 3.9 | 16.7 | — | — | — |
| Price / book | 1.4 | 1.6 | 2.1 | 2.0 | 1.8 | — | — |
| Price / free cash flow | — | — | 3.7 | — | — | — | — |
| Price / operating cash flow | — | — | 3.6 | — | — | — | — |
| EV / sales | 7.1 | 1.5 | 1.7 | 10.3 | — | — | — |
| EV / EBITDA | — | 4.5 | 14.4 | — | — | — | — |
| EV / free cash flow | — | — | 1.6 | — | — | — | — |
| Earnings yield | −33.8% | 9.7% | −1.3% | −20.7% | −9.4% | — | — |
| Free cash flow yield | −30.5% | −6.6% | 26.9% | −22.8% | −10.4% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $10.28 | $17.29 | $15.09 | $13.52 | $17.12 | — | — |
| Per share | |||||||
| Revenue per share | $0.61 | $5.40 | $3.90 | $0.81 | $0.00 | $0.00 | — |
| Earnings per share | −$3.47 | $1.68 | −$0.20 | −$2.79 | −$1.60 | −$0.85 | — |
| Operating cash flow per share | −$3.11 | −$1.07 | $4.23 | −$3.00 | −$1.63 | −$0.82 | — |
| Free cash flow per share | −$3.13 | −$1.15 | $4.06 | −$3.09 | −$1.78 | −$0.89 | — |
| Cash per share | $7.15 | $10.77 | $10.65 | $6.03 | $9.32 | $1.25 | — |
| Book value per share | $7.40 | $10.99 | $7.33 | $6.79 | $9.57 | −$1.33 | — |
| Tangible book value per share | $7.40 | $10.99 | $7.33 | $6.79 | $9.57 | −$1.33 | — |
| Capex per share | $0.03 | $0.08 | $0.17 | $0.09 | $0.15 | $0.07 | — |
| Debt per share | $1.23 | $1.52 | $2.06 | $0.83 | — | — | — |
| Shares outstanding | 41.4M | 39.0M | 33.1M | 31.3M | 31.2M | 31.2M | — |
| Change in shares outstanding | +6.1% | +18.0% | +5.6% | +0.2% | −0.1% | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −39.1% | 19.6% | −2.9% | −34.2% | −38.9% | — | — |
| Return on invested capital (ROIC) | −190.7% | 350.1% | — | −267.5% | — | — | — |
| Return on assets (ROA) | −31.8% | 13.2% | −1.9% | −31.4% | −28.7% | −85.9% | −25.5% |
| Return on tangible assets | −38.1% | 12.5% | −1.4% | −34.7% | −16.4% | −60.9% | −25.5% |
| Free cash flow margin | −509.6% | −21.2% | 104.0% | −382.7% | — | — | — |
| Income quality (OCF / net income) | — | −0.63 | — | — | — | — | — |
| Financial health | |||||||
| Total debt | $50.9M | $59.2M | $68.2M | $25.9M | — | — | — |
| Cash & short-term investments | $295.7M | $420.0M | $352.0M | $188.7M | $291.1M | $39.0M | $16.8M |
| Net debt | −$244.8M | −$360.8M | −$283.7M | −$162.8M | −$291.1M | −$39.0M | −$16.8M |
| Debt / equity | 0.17 | 0.14 | 0.28 | 0.12 | — | — | — |
| Debt / assets | 0.13 | 0.11 | 0.15 | 0.10 | — | — | — |
| Net debt / EBITDA | — | −5.14 | −19.05 | — | — | — | — |
| Current ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Quick ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Interest coverage | — | — | — | -36.9 | — | — | — |
| Working capital | $281.8M | $400.6M | $211.0M | $187.9M | $292.0M | $36.6M | $15.5M |
| Invested capital | $61.4M | $67.9M | −$41.4M | $49.8M | $7.7M | −$80.5M | −$32.4M |
| Tangible asset value | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M | −$41.5M | −$15.5M |
| Net current asset value | $235.0M | $342.4M | $142.9M | $170.4M | $291.6M | −$45.1M | −$16.3M |
| Graham number | — | $20.40 | — | — | — | — | — |
| Graham net-net per share | $5.47 | $8.34 | $3.92 | $4.77 | $9.11 | −$1.47 | — |
| Capital allocation | |||||||
| Share buybacks (net) | $0 | $0 | $0 | $0 | $0 | — | — |
| Dividends + buybacks / free cash flow | — | — | 0.0% | — | — | — | — |
| Capex / revenue | 4.1% | 1.5% | 4.4% | 11.4% | — | — | — |
| Capex / operating cash flow | — | — | 4.0% | — | — | — | — |
| Capex / depreciation | 0.25 | 0.84 | 1.98 | 1.52 | 4.10 | 7.11 | 6.06 |
| Stock-based compensation / revenue | 77.1% | 8.5% | 10.2% | 39.2% | — | — | — |
| R&D / revenue | 559.7% | 59.4% | 77.4% | 263.7% | — | — | — |
| SG&A / revenue | 161.5% | 18.2% | 25.0% | 121.3% | — | — | — |
| Efficiency | |||||||
| Days sales outstanding | 44.9 | 8.3 | 16.6 | — | — | — | — |
| Days of inventory on hand | — | — | 0.0 | — | — | — | — |
| Days payables outstanding | 291.8 | 364.5 | 16.9 | 644.9 | 377.1 | 1,294.3 | 2,491.8 |
| Cash conversion cycle (days) | -246.8 | -356.2 | -0.3 | — | — | — | — |
| Receivables turnover | 8.13 | 44.11 | 21.95 | — | 0.00 | — | — |
| Payables turnover | 1.25 | 1.00 | 21.56 | 0.57 | 0.97 | 0.28 | 0.15 |
| Inventory turnover | — | — | 99,884,000.00 | — | — | — | — |
| Asset turnover | 0.06 | 0.42 | 0.36 | 0.09 | 0.00 | 0.00 | 0.00 |
| Average receivables | $3.1M | $4.8M | $5.9M | — | $872,000 | — | — |
| Average payables | $3.3M | $3.8M | $4.6M | $3.3M | $1.2M | $1.2M | $710,000 |
| Average inventory | — | — | $1 | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from TRDA's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
TRDA valuation and financial ratios
Entrada Therapeutics earned a return on equity of −39.1% and a return on invested capital of −190.7% in fiscal 2025. It ended the year with $50.9 million of debt and $295.7 million in cash and short-term investments, a net cash position of $244.8 million.
See the TRDA income statement, the TRDA chart for price history, or the TRDA stock overview for the latest quote and news.
TRDA key metrics FAQ
What is Entrada Therapeutics's return on equity?
Entrada Therapeutics's return on equity (ROE) was −39.1% in fiscal 2025: net income of -$143.8 million on average shareholders' equity of $367.4 million.
What is Entrada Therapeutics's ROIC?
Entrada Therapeutics's return on invested capital was −190.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Entrada Therapeutics have?
Entrada Therapeutics had total debt of $50.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.17 and more cash than debt.
What is Entrada Therapeutics's free cash flow yield?
Entrada Therapeutics generated -$129.6 million of free cash flow in fiscal 2025, a free cash flow yield of −30.5% on its market value at year-end ($425.3 million).
What is Entrada Therapeutics's current ratio?
Entrada Therapeutics's current ratio was 12.53 at the end of fiscal 2025: current assets were 12.53 times current liabilities.